Seagen, Mer­ck­'s Pad­cev-Keytru­da com­bo snags FDA ac­cel­er­at­ed ap­proval for blad­der can­cer

Seagen’s Pad­cev and Mer­ck’s Keytru­da have been cleared by the FDA as a com­bo for first-line treat­ment of blad­der can­cer, po­ten­tial­ly push­ing Pad­cev in­to a multi­bil­lion-dol­lar mar­ket just as Pfiz­er pre­pares to con­sum­mate its $43 bil­lion buy­out of Seagen.

The FDA hand­ed out the ac­cel­er­at­ed ap­proval based on pos­i­tive da­ta from a mul­ti-co­hort study with Pad­cev (en­for­tum­ab ve­dotin) and Keytru­da (pem­brolizum­ab) in pa­tients with lo­cal­ly ad­vanced or metasta­t­ic urothe­lial can­cer who are in­el­i­gi­ble for cis­platin-con­tain­ing chemother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER